Inequalities in pharmacologic treatment of spasticity in Sweden – health economic consequences of closing the treatment gap

Table 2 Incremental cost for regional treatment equity

Healthcare region	Total incremental number of BoNT-A treatment sessions^a	Total incremental cost per year^b (EUR 2017)	Total incremental number of ITB pumps^c	Total incremental cost per year^d (EUR 2017)
Stockholm-Gotl.	946	542,999	250	1,033,523
Örebro-Uppsala	833	656,135	201	833,023
Western	1143	222,295	176	727,773
Southern^e	–	–	137	567,799
South Eastern	387	477,924	40	164,573
Northern^e	135	77,420	–	–
Total	3443	1,976,773	804	3,326,692

^aAssuming highest level reported by the healthcare regions (13.6%) corresponds to optimal level
^bBased on the mean procedural cost per patient for EMG-guided injection of botulinum toxin for ICD-codes G811, G821 and G824 (~EUR 574). Source: Cost Per Patient database (2017), Swedish Association of Local Authorities and Regions
^cAssuming highest level reported by the healthcare regions (14.1/100,000) corresponds to optimal level
^dBased on the total cost for implantation of pump, drug costs and three refills of 30 ml per year
^eThese healthcare regions used as reference for treatment equity of BoNT-A treatment and ITB pumps, respectively. Hence no values for incremental number are assigned

ISSN: 2191-1991